Peter Chen, MD
Pulmonary Disease · Seattle, WANPI 1225100183
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,288 of the $17,943 with a category attached, or 74.1%. 7 manufacturers reported payments, led by Gilead at 51.3% of the total. Reporting peaked in 2021 at $9,488 and has fallen 98.6% since, to $129 in 2025. Among pulmonary disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $747.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$9K
- Lilly USA, LLC$3K
- Life Technologies Corporation$3K
- Rigel Pharmaceuticals, Inc.$2K
- Eli Lilly$525
- Edwards Lifesciences$129
- plus $75 from 1 others
Across 32 payments — averaging $83,677 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.6M
- Gilead$59K
- Regeneron$27K
- Boehringer Ingelheim$9K
What the payments were for
- Consulting fees$13,28874%
- Speaking & faculty fees$3,20018%
- Travel & lodging$8325%
- Food & beverage$6233%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $9,201 |
| Lilly USA, LLC | 3 | $3,413 |
| Life Technologies Corporation | 2 | $2,800 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,800 |
| Eli Lilly | 1 | $525 |
| Edwards Lifesciences | 1 | $129 |
| Abbott | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$8,719
- Tavalisse$1,800
- Edwards SAPIEN 3 Transcatheter Heart Valve$129
How this compares
$17,943 in reported general payments places this provider in the 90th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $17,573 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,562 |
| MethotrexateMethotrexate Sodium | 13 | $170 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Seattle
- Jed GordenSeattle$236K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Jeffrey CarySeattle$106K
- Amy DickeySeattle$71K
- Lawrence HoSeattle$70K
- Christopher GossSeattle$44K
- Reena MehraSeattle$36K
- Rebecca SellSeattle$30K
- Peter LearySeattle$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.